This paper analyzes the strategic alliance between pharmaceutical firms Crawford-Beckman and Wilson through four key dimensions: alliance type, partner fit, structural design, and value creation. Crawford-Beckman developed a promising diabetes drug but lacked the marketing infrastructure to compete with industry giants. Wilson brought established physician relationships and sales expertise but needed a blockbuster product. Their co-promotional agreement created a shared-cost, shared-revenue structure that generated early success yet also produced internal resentment over unequal resource contributions. The paper identifies the strengths and weaknesses of the partnership and concludes that clearer cost-sharing mechanisms are necessary for long-term viability in the lucrative and growing diabetes market.
The partnership between Crawford-Beckman and Wilson took the form of a co-promotional agreement. Both companies agreed to share the expenses of marketing the drug, as well as all subsequent research for it and for any future drugs developed jointly. Originally, the two firms were competitors within the pharmaceutical and consumer products industry. Wilson had a much stronger record in the pharmaceuticals market, while Crawford-Beckman's strengths lay primarily in the consumer products line.
Crawford-Beckman had developed a promising diabetes drug but lacked the marketing and sales infrastructure needed to promote it aggressively. Wilson, by contrast, possessed a top-flight marketing and sales staff, a strong industry reputation, and — critically — established relationships with the physicians who would be central to advocating the new drug to patients.
Crawford-Beckman had struggled to make inroads into the lucrative pharmaceutical field and lacked the resources of established competitors such as Eli Lilly. Wilson, for its part, was eager to partner because of the diabetes drug's growth potential. The company had long sought a blockbuster diabetes product to challenge rivals including Pfizer, Eli Lilly, and Bristol-Myers Squibb. By partnering with Crawford-Beckman, Wilson could pursue that goal while simultaneously ensuring that its smaller rival would not gain independent traction in the pharmaceutical market.
Under the terms of the agreement, Wilson would receive 30 percent of net revenues, rising to 50 percent if the product emerged as a true blockbuster. Each project team would include a representative from both companies, while the structural integrity of each firm would remain intact. There was a contractual obligation for both parties to contribute equally to marketing expenses, although Betton Therapeutics — a division of Crawford-Beckman — would serve as the final arbiter of production, legal, accounting, and other financial decisions.
Wilson brought a built-in sales structure capable of increasing demand among physicians, along with established knowledge of how to reach and compete against rival firms. Crawford-Beckman contributed the drug that Wilson needed. As a smaller company seeking to expand its pharmaceutical portfolio, Crawford-Beckman also benefited from a provision specifying that the two firms would co-develop a new drug in the future.
The companies would remain structurally separate, but a new collaborative structure was created to support the partnership, with specific delegation of responsibilities within the joint team. The joint divisions were, in general, designed as partnerships of equals, reflecting the strategic alliance principle that both parties must perceive mutual benefit for cooperation to be sustained.
"Cost-sharing resentment undermines early partnership success"
"Clearer marketing cost structures needed for survival"
You’re 64% through this paper. Sign up to read the remaining 2 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.